The Joe Tippens Protocol: Myths vs. Evidence — What They Don't Tell You

In this investigation, we dissect the Joe Tippens protocol claim by claim — separating verified science from viral mythology, and revealing critical details most sources conveniently omit.

Quick Overview

• Author: Joe Tippens
• Goal: Anti-cancer supplementation protocol based on fenbendazole combined with supporting compounds
• Duration: Original cycle: 3 days on / 4 days off; Updated version: daily, no breaks
• Key compounds: Fenbendazole, vitamin E succinate, curcumin, CBD oil
• Cycles: Indefinite, with prophylactic variants for survivors and healthy individuals

Overview

The Joe Tippens protocol is a self-reported supplementation regimen centered on fenbendazole, a broad-spectrum anthelmintic drug used in veterinary medicine. The protocol gained widespread attention after Joe Tippens, diagnosed in 2016 with stage IV small-cell lung cancer with metastases throughout his body, reported significant improvement on subsequent PET scans after beginning the regimen in January 2017. The suggestion to use fenbendazole came from a veterinarian acquaintance who had observed unexpected tumor suppression in laboratory animals receiving the compound.

Tippens combined fenbendazole with vitamin E succinate, curcumin, and CBD oil in his original protocol. He has documented his ongoing regimen on his personal blog, mycancerstory.rocks. Over time, he updated the protocol to include daily fenbendazole use and additional proprietary supplement formulations marketed as the Onco Adjunct Pathway series. Maintenance and prophylactic versions of the protocol have also been described for cancer survivors and people without a cancer diagnosis.

The protocol has not been evaluated in formal clinical trials as a combined regimen. Laboratory research has identified plausible mechanisms by which fenbendazole may affect cancer cells, but no controlled human studies have confirmed the efficacy or safety of this specific combination at these doses. The information presented below is for educational purposes only.

Dosage and Schedule

Original Protocol (3 days on / 4 days off)

This is the protocol Tippens used when actively addressing cancer. The 3-days-on / 4-days-off cycle was based on his personal experience.

• Fenbendazole: 222 mg once daily for 3 consecutive days, then 4 days off. One gram of Panacur C or Safeguard granules (which contain 222 mg of fenbendazole per gram of product). Always taken with a fatty meal to improve absorption. Liquid form (100 mg/ml): 2.2 ml daily on dosing days.
• Vitamin E succinate: 400–800 mg daily, 7 days a week. Tippens used Gamma E (Life Extension) or Perfect E (Vitamin Discount Center).
• Curcumin: 600 mg — 2 tablets daily, 7 days a week. Tippens used Theracurmin HP (Integrative Therapeutics).
• CBD oil: 25 mg daily, 7 days a week.

Updated Protocol (daily, no breaks)

After his initial period of recovery, Tippens updated his protocol. The updated version removes the 3-days-on / 4-days-off cycle in favor of continuous daily fenbendazole use and incorporates the Onco Adjunct Pathway supplements.

• Fenbendazole: 222 mg every day, no breaks. Liquid form: 2.2 ml daily.
• Onco Adjunct Pathway 1: 2–4 ml twice daily, dose based on body weight.
• Onco Adjunct Pathway 2: 3 capsules twice daily — taken only when not on chemotherapy.
• Onco Adjunct Pathway 3: 1 capsule with a light meal, 2 capsules with a heavy meal. Described as designed to reduce cancer cell access to glucose.
• Onco Adjunct Pathway 4: 2 capsules twice daily.

Mechanism of Action

Fenbendazole

Fenbendazole belongs to the benzimidazole class of anthelmintics, which act primarily by binding to tubulin and disrupting the tubulin-microtubule equilibrium in parasites. In a 2018 study published in Scientific Reports, Dogra et al. demonstrated that fenbendazole exerts cytotoxicity in human cancer cell lines through three concurrent mechanisms: moderate destabilization of microtubule polymerization (interfering with mitotic spindle formation), activation and mitochondrial translocation of the p53 tumor suppressor protein (promoting apoptosis), and inhibition of glucose uptake through downregulation of GLUT transporter proteins and hexokinase II (HKII), a key glycolytic enzyme. In a mouse xenograft model, orally administered fenbendazole reduced tumor size and vascularity. Cells with wild-type p53 showed enhanced sensitivity to fenbendazole-induced apoptosis.

A separate study by Gao, Dang, and Watson (2008) in the Journal of the American Association for Laboratory Animal Science found that fenbendazole alone did not significantly inhibit tumor growth in SCID mice, but the combination of fenbendazole with supplementary vitamins produced significant tumor growth inhibition. The mechanism of this synergy was not established. These findings suggest that the combination of compounds in the protocol may be relevant to any observed effect, and that fenbendazole in isolation may have limited activity in some models.

Vitamin E Succinate

Vitamin E succinate (alpha-tocopheryl succinate, alpha-TOS) is a redox-silent ester of vitamin E. Unlike alpha-tocopherol (the standard form of vitamin E), alpha-TOS has been shown to induce apoptosis selectively in malignant cells without significant toxicity to normal cells. Studies published in Cancer Research (Neuzil et al., 2002) and the British Journal of Cancer (Neuzil et al., 2003) describe the compound’s ability to trigger mitochondrial apoptotic pathways, mobilize Fas receptor activity, and cooperate with TRAIL in suppressing tumor growth in vivo. Its anticancer activity is attributed to the succinate ester group rather than antioxidant properties; it functions through a pro-apoptotic rather than antioxidant mechanism.

Curcumin

Curcumin is the principal bioactive polyphenol in turmeric (Curcuma longa). Laboratory studies have shown that curcumin inhibits cancer cell proliferation and induces apoptosis through multiple pathways, including activation of p53, suppression of NF-kB and STAT3 signaling, inhibition of the Akt/mTOR pathway, and induction of reactive oxygen species (ROS)-mediated mitochondrial cell death. A review published in Biomedicines (2021) summarizes curcumin’s documented activity across multiple cancer types in preclinical models. Bioavailability of standard curcumin formulations is limited; highly bioavailable forms such as Theracurmin (the brand specified by Tippens) have been developed to improve systemic absorption.

CBD Oil

Cannabidiol (CBD) is a non-psychoactive cannabinoid derived from Cannabis sativa. A 2022 review published in Biology ( Hung et al.) summarizes preclinical evidence suggesting CBD induces apoptosis and inhibits invasion, migration, and metastasis in cancer cell lines through mechanisms including activation of CB1, CB2, and TRPV1 receptors, induction of ROS, and modulation of pro- and anti-apoptotic proteins. Most evidence is derived from in vitro and animal studies. Tippens included CBD oil at 25 mg per day in both the original and prophylactic protocols; the specific contribution of CBD to any observed effect in humans remains unclear.

Optional and Alternative Variants

For Cancer Survivors (relapse prevention)

Once cancer is in remission, Tippens recommends a reduced maintenance schedule rather than stopping the regimen entirely.

• Fenbendazole: 222 mg, 3 times per week (for example, Monday / Wednesday / Friday), taken with a fatty meal. Repeat indefinitely.
• Curcumin: 600 mg — 2 tablets daily, no breaks.
• CBD oil: 25 mg daily, no breaks.
• Monitoring: Tumor marker blood tests every few months. Annual full imaging. After 5 years cancer-free, testing frequency may be reduced.

For Healthy Individuals (prophylactic use)

• Fenbendazole: 222 mg, 3 times per week, taken with a fatty meal. Take for 10 weeks, then stop for 10 weeks. Repeat the cycle.
• Curcumin: 600 mg — 2 tablets daily, no breaks.
• CBD oil: 25 mg daily, no breaks.

Important Considerations

Fenbendazole is not approved by any regulatory authority for the treatment of cancer in humans. All laboratory evidence for its anti-neoplastic activity is derived from in vitro studies and animal models. No randomized controlled clinical trials have evaluated the efficacy or safety of fenbendazole as a cancer therapy in humans, nor has this specific combination regimen been assessed in formal studies.

The Onco Adjunct Pathway products referenced in the updated protocol are proprietary formulations with no independent clinical trial data. Their inclusion reflects Tippens’ personal protocol evolution and should not be interpreted as evidence of efficacy.

Fenbendazole may interact with other medications and treatments. The combination of multiple bioactive compounds at these doses may affect liver enzyme function, drug metabolism (particularly cytochrome P450 pathways), or the efficacy of concurrent chemotherapy. Curcumin at high doses has known interactions with anticoagulants and other drugs. CBD may interact with medications metabolized by the CYP450 system.

Reports of self-administration of fenbendazole in cancer patients have documented cases where it was taken without physician supervision and concurrent with other treatments, making it impossible to attribute observed outcomes to fenbendazole specifically.

This protocol has not been evaluated in formal clinical trials as a combined regimen. The information presented is for educational purposes only. Always consult a qualified healthcare professional before starting any new treatment protocol.

How the Protocol Went Viral

The protocol's reach is inseparable from its origin story. In 2016 Joe Tippens, a former materials-industry executive from Oklahoma, was diagnosed with small-cell lung cancer; by the following year it had metastasised widely and he was given a terminal prognosis. On the advice of a veterinarian he began taking fenbendazole alongside a clinical trial of the immunotherapy drug pembrolizumab (Keytruda). When his subsequent scans showed no detectable disease, he published the account on his blog, mycancerstory.rocks, in 2018.

The post spread rapidly through Facebook groups and YouTube, and the regimen became known as the "Joe Tippens protocol." It is essential to note that Tippens received a checkpoint inhibitor at the same time — a therapy independently associated with durable remissions in a subset of lung-cancer patients. Because the two interventions ran concurrently, his individual outcome cannot be attributed to fenbendazole alone, a limitation Tippens himself has acknowledged.

Liver Safety and Monitoring

The single most important documented risk of sustained fenbendazole use in humans is drug-induced liver injury (DILI). Fenbendazole is metabolised in the liver, and several peer-reviewed case reports now describe serious hepatotoxicity in people who self-administered it for cancer:

• A 67-year-old woman presented with two weeks of jaundice and was found to have histologically confirmed severe hepatocellular liver injury after self-administering fenbendazole — reported as the first biopsy-confirmed case of its kind (Thakurdesai et al., ACG Case Reports Journal, 2024).
• A patient with non-small-cell lung cancer developed DILI after starting fenbendazole based on social-media information (Yamaguchi et al., Case Reports in Oncology, 2021).
• A 47-year-old woman with metastatic colon cancer on immunotherapy developed severe hepatocellular injury after increasing her self-administered fenbendazole dose; clinicians used the Roussel Uclaf Causality Assessment Method (RUCAM) and scored the case "probable" for fenbendazole (score 8).

In each case, liver function improved after the drug was stopped, indicating the injury was largely reversible on discontinuation. A recurring diagnostic challenge is that patients on immune-checkpoint inhibitors can also develop immunotherapy-induced hepatitis, making it difficult to separate the two causes without careful workup.

Practical monitoring, if used under medical supervision:

• Obtain a baseline liver-function panel (ALT, AST, ALP, bilirubin) before starting.
• Recheck every 4–6 weeks during the first six months.
• Pause fenbendazole if ALT or AST rises above roughly 2–3× the upper limit of normal, and seek medical review.
• Report any jaundice, dark urine, right-upper-quadrant pain, or unusual fatigue immediately.

Reported Side Effects

Beyond the liver, side effects reported by users are largely anecdotal rather than trial-derived. The table below summarises what has been described in case reports and community accounts, with an honest note on the strength of evidence for each.

The absence of controlled trials means the true frequency of any of these effects is unknown, and rare or delayed harms may not yet be documented.

Drug Interactions and Sourcing Risks

Interactions. Fenbendazole and the protocol's supplements are metabolised through hepatic cytochrome-P450 pathways, so overlap with prescription drugs is plausible. Curcumin can affect anticoagulants and may interfere with chemotherapies or radiation that rely on oxidative stress; CBD inhibits several CYP450 enzymes and can raise or lower levels of co-administered medicines. This is why the original vitamin-E component was later dropped from the "official" protocol over bleeding-risk concerns.

Sourcing and quality control. Most fenbendazole taken for this purpose is sold as a veterinary product (for example Panacur C or Safe-Guard). Veterinary manufacturing is not held to human-pharmaceutical standards for dose uniformity, excipient testing, or contaminant limits, so potency and purity can vary between batches. Human-labelled "research" capsules are likewise sold without regulatory approval or verified quality control.

Related Protocols and Further Reading

The Joe Tippens regimen is one of several repurposed-drug approaches discussed on this site. For balanced, sourced comparisons see:

• Fenbendazole, Berberine & Curcumin Protocol
• High-Dose Fenbendazole Protocol
• Fenbendazole & Vitamin E Synergy Protocol
• Fenbendazole Case Reports & Clinical Evidence
• Maximising Fenbendazole Absorption

Sources